Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 8, 2004, Pages 345-352

  Dutta, Sandeep ^a   Zhang, Yiming ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Bioequivalence; Divalproex sodium; Modified release; Pharmacokinetics; Sustained release; Valproate

Indexed keywords

VALPROATE SEMISODIUM;

AREA UNDER THE CURVE; ARTICLE; CALORIC INTAKE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; EPILEPSY; FOOD DRUG INTERACTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; REFERENCE VALUE; STATISTICAL SIGNIFICANCE; STEADY STATE; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION;

ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; EPILEPSY; HUMANS; META-ANALYSIS; THERAPEUTIC EQUIVALENCY; VALPROIC ACID;

EID: 8844223384     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.420     Document Type: Article

References (10)

1. Depakote® Tablets Product Information. Divalproex Sodium Delayed-Release Tablets. Abbott Laboratories, Inc.: North Chicago, IL 60064, USA, 2002.
2. Depakote® ER Tablets Product Information. Divalproex Sodium Extended-Release Tablets. Abbott Laboratories, Inc.: North Chicago, IL 60064, USA, 2003.
3. Cavanaugh JH, Granneman R, Lamm J, et al. Effect of food on the bioavailability of a controlled-release formulation of Depakote under multiple-dose conditions. Epilepsia 1997; 38 Suppl. 8): 54.
4. Samara E, Granneman R, Achari R, et al. Bioavailability of a controlled-release formulation of depakote. Epilepsia 1997; 38(Suppl. 8): 102.
5. Dutta S, Reed RC. Divalproex to divalproex extended release conversion. Clin Drug Invest 2004; 24(9): 495-508.
6. Dutta S, Zhang Y, Selness DS, et al. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res 2002; 49: 1-10.
7. Sommerville KW, Dutta S, Biton V, et al. Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme- inducing antiepileptic drugs. Clin Drug Invest 2003; 23: 661-670.
8. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002; 21: 589-624.
9. Fieller EC. Some problems in interval estimation. J R Stat Soc 1954; Series B 16: 175-185.
10. Chadwick DW. Concentration-effect relationships of valproic acid. Clin Pharmacokinet 1985; 10: 155-163.